SQM and Wesfarmers Greenlight $450M–$500M Mt Holland Lithium Expansion to Double Output
SQM sits 93% above its 52-week low of $35.67.
Summary
SQM and Wesfarmers approved a final investment decision to double Mt Holland lithium production, with SQM's share of capex estimated at US$450–500 million. First production from the expansion is expected in 2030.
Key Events · M&A and Partnerships · SQM
-
Mt Holland Expansion Approved
A final investment decision has been approved to double spodumene concentrate production at the Mt Holland lithium project from ~380,000 tonnes per year to 760,000 tonnes per year.
-
SQM's Capex Commitment
SQM's share of the expansion capital expenditure is estimated at US$450 million to US$500 million in nominal terms, excluding life-of-mine capex.
-
Timeline and First Production
Construction of a second concentrator is expected to begin in the second half of 2027, with first spodumene concentrate production volumes from the expansion expected in the first half of 2030.
-
Strategic Rationale
The expansion aims to lower unit operating costs and strengthen SQM's position on the global lithium cost curve, with optionality to supply future downstream processing or sell spodumene concentrate directly.
Analysis · SQM · Energy & Transportation
Together with JV partner Wesfarmers, SQM has committed US$450–500 million in capex to double spodumene concentrate output at Mt Holland to 760,000 tonnes per year. The decision underscores a long-term lithium growth strategy and a stronger position on the global cost curve. While first production is not expected until 2030—leaving near-term cash flows untouched—the move signals confidence in sustained demand driven by the energy transition.
At the time of this filing, SQM was trading at $68.93 on NYSE in the Energy & Transportation sector, with a market capitalization of approximately $18.4B. The 52-week trading range was $35.67 to $98.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.